scholarly journals Effect of Short-Course Oral Ciprofloxacin on Isoflavone Pharmacokinetics following Soy Milk Ingestion in Healthy Postmenopausal Women

2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Nathathai Temyingyong ◽  
Nut Koonrungsesomboon ◽  
Nutthiya Hanprasertpong ◽  
Mingkwan Na Takuathung ◽  
Supanimit Teekachunhatean
Keyword(s):  
Oral Dose ◽  
Gut Microbiota ◽  
Single Oral Dose ◽  
Postmenopausal Women ◽  
Plasma Concentrations ◽  
Soy Milk ◽  
Blood Samples ◽  
Short Course ◽  
Oral Ciprofloxacin ◽  
Milk Ingestion

Soy isoflavones have several potential benefits related to postmenopausal health. Isoflavone glycosides, found predominantly in nonfermented soy products, e.g., soy milk, require conversion by gut microbiota to their respective bioavailable aglycones prior to absorption into portal circulation. Use of short-course oral ciprofloxacin for the treatment of acute uncomplicated cystitis, the incidence of which is increasing among postmenopausal women, might adversely affect gut microbiota. The objective of this one-group pre-post treatment study was to determine the effect of short-course oral ciprofloxacin on isoflavone pharmacokinetics in healthy postmenopausal women. Eleven postmenopausal subjects were assigned to consume a single oral dose of 375 mL UHT soy milk (SOY phase). Blood samples were collected immediately before soy milk ingestion and at specific times for 32 hours after soy milk ingestion. Following a washout period of at least seven days, subjects were assigned to take 250 mg oral ciprofloxacin after breakfast and dinner for three days, followed by a single oral dose of 375 mL UHT soy milk the next day (CIPRO/SOY phase). Blood samples were collected at the same time points as in the SOY phase. Plasma samples were treated withβ-glucuronidase/sulfatase and plasma concentrations of aglycones (genistein and daidzein) were determined using high-performance liquid chromatography.Cmax,AUC0-t, andAUC0-∞of both aglycones andTmaxof genistein obtained from the CIPRO/SOY phase were significantly lower than those obtained from the SOY phase, whileTmaxof daidzein and t1/2of both aglycones in the two phases were not significantly different.

scholarly journals Effects of the Chinese Herbal Formulation (Liu Wei Di Huang Wan) on the Pharmacokinetics of Isoflavones in Postmenopausal Women

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Wirin Limopasmanee ◽  
Sunee Chansakaow ◽  
Noppamas Rojanasthien ◽  
Maleeya Manorot ◽  
Chaichan Sangdee ◽  
...  
Keyword(s):  
Plasma Concentration ◽  
Oral Dose ◽  
Single Oral Dose ◽  
Postmenopausal Women ◽  
Pharmacokinetic Parameters ◽  
Soy Milk ◽  
Open Label ◽  
Fixed Sequence ◽  
Time Curve ◽  
Oral Doses

A combination of soy isoflavones andLiu Wei Di Huang Wan(LWDHW) is potentially effective for postmenopausal women with intolerable vasomotor episodes who are not suitable candidates for hormonal therapy. The objective of this open-label, three-phase, crossover study was to determine the influence of both single and multiple oral doses of LWDHW on isoflavone pharmacokinetics in healthy postmenopausal women. Eleven subjects were assigned to receive the following regimens in a fixed sequence with washout periods of at least one week: Phase A, a single oral dose of soy milk; Phase B, a single oral dose of soy milk coadministered with LWDHW; and Phase C, multiple oral doses of LWDHW for 14 days followed by a single oral dose of soy milk. Blood samples were collected and mixed withβ-glucuronidase/sulfatase to hydrolyze isoflavone conjugates to their respective aglycones (i.e., daidzein and genistein) and were determined using high performance liquid chromatography. The pharmacokinetic parameters analyzed were maximal plasma concentrationCmax, time to reach peak concentrationTmax, area under the plasma concentration-time curve (AUC), and half-life (t1/2). The results found no statistically significant differences in pharmacokinetic parameters of daidzein and genistein among the three regimens.

scholarly journals Influence of Fructooligosaccharide on Pharmacokinetics of Isoflavones in Postmenopausal Women

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Supanimit Teekachunhatean ◽  
Sujitra Techatoei ◽  
Noppamas Rojanasthein ◽  
Maleeya Manorot ◽  
Chaichan Sangdee
Keyword(s):  
Oral Dose ◽  
Single Oral Dose ◽  
Postmenopausal Women ◽  
Pharmacokinetic Parameters ◽  
Two Phase ◽  
Fixed Sequence ◽  
Blood Samples ◽  
Single Oral Administration ◽  
Oral Doses ◽  
To Receive

The objective of the present paper was to determine the influence of fructooligosaccharide (FOS) on the pharmacokinetics of isoflavones in healthy postmenopausal women. The study was a fixed-sequence, two-phase, crossover study. Twelve subjects received a single oral dose of 300 mL of a soy beverage. Blood samples were collected before the dose and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, and 32 h after the administration of the soy beverage. After a washout period of at least 1 week, subjects were assigned to receive oral doses of FOS, 5 g each time, twice a day (after breakfast and dinner) for 14 days, followed by a single oral dose of the same soy beverage on the next day. Blood samples were then collected at the same time points mentioned previously. Plasma isoflavone concentrations were determined by HPLC. Continuous oral administrations of FOS followed by a single oral administration of soy beverage caused significant increases inCmax, AUC0–32, and AUC0–∞of genistein and AUC0–32of daidzein, comparing to those obtained following a single oral dose of soy beverage alone. Other pharmacokinetic parameters (Tmaxandt1/2of both aglycones and AUC0–∞of daidzein) between both regimens were not significantly different.

scholarly journals Milk polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay

Gut ◽  
2019 ◽  
Vol 69 (3) ◽  
pp. 487-501 ◽  
Author(s):  
Cécile Vors ◽  
Laurie Joumard-Cubizolles ◽  
Manon Lecomte ◽  
Emmanuel Combe ◽  
Lemlih Ouchchane ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Postmenopausal Women ◽  
Plasma Concentrations ◽  
Cholesterol Absorption ◽  
Polar Lipids ◽  
Lipid Absorption ◽  
Cardiometabolic Health ◽  
Apo B ◽  
Link Type ◽  
Randomised Controlled

ObjectiveTo investigate whether milk polar lipids (PL) impact human intestinal lipid absorption, metabolism, microbiota and associated markers of cardiometabolic health.DesignA double-blind, randomised controlled 4-week study involving 58 postmenopausal women was used to assess the chronic effects of milk PL consumption (0, 3 or 5 g-PL/day) on lipid metabolism and gut microbiota. The acute effects of milk PL on intestinal absorption and metabolism of cholesterol were assessed in a randomised controlled crossover study using tracers in ileostomy patients.ResultsOver 4 weeks, milk PL significantly reduced fasting and postprandial plasma concentrations of cholesterol and surrogate lipid markers of cardiovascular disease risk, including total/high-density lipoprotein-cholesterol and apolipoprotein (Apo)B/ApoA1 ratios. The highest PL dose preferentially induced a decreased number of intestine-derived chylomicron particles. Also, milk PL increased faecal loss of coprostanol, a gut-derived metabolite of cholesterol, but major bacterial populations and faecal short-chain fatty acids were not affected by milk PL, regardless of the dose. Acute ingestion of milk PL by ileostomy patients shows that milk PL decreased cholesterol absorption and increased cholesterol-ileal efflux, which can be explained by the observed co-excretion with milk sphingomyelin in the gut.ConclusionThe present data demonstrate for the first time in humans that milk PL can improve the cardiometabolic health by decreasing several lipid cardiovascular markers, notably through a reduced intestinal cholesterol absorption involving specific interactions in the gut, without disturbing the major bacterial phyla of gut microbiota.Trial registration numberNCT02099032 and NCT02146339; Results.

Parenteral corticosteroids in emergency

1967 ◽  
Vol 5 (2) ◽  
pp. 6-7
Keyword(s):  
Oral Dose ◽  
Single Oral Dose ◽  
Corticosteroid Therapy ◽  
Plasma Concentrations ◽  
Addison’S Disease ◽  
Sudden Increase ◽  
Adrenal Failure ◽  
Intravenous Therapy ◽  
Intramuscular Dose ◽  
Acute Adrenal Failure

Corticosteroids are well absorbed from the gut: plasma concentrations of prednisolone or hydrocortisone are at a maximum about 2 hours after a single oral dose.1 An intramuscular dose acts no more quickly. Intravenous corticosteroid acts at once and is required for severe acute adrenal failure, for example in the crises of Addison’s disease, after adrenalectomy, after sudden cessation of corticosteroid therapy and sometimes in severe hypopituitarism. A sudden increase in the requirement of patients who are taking or have taken corticosteroids may also demand intravenous therapy.

scholarly journals Food–Drug Interaction between the Adlay Bran Oil and Drugs in Rats

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2473 ◽  
Author(s):  
Hsien-Tsung Yao ◽  
Jia-Hsuan Lin ◽  
Yun-Ta Liu ◽  
Mei-Ling Li ◽  
Wenchang Chiang
Keyword(s):  
Oral Dose ◽  
Drug Interactions ◽  
Single Oral Dose ◽  
Plasma Concentrations ◽  
Oral Drug ◽  
Drug Cocktail ◽  
Intestinal Drug Absorption ◽  
Drug Concentrations ◽  
Plasma Theophylline ◽  
Term Administration

Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) contains various phytonutrients for treating many diseases in Asia. To investigate whether orally administered adlay bran oil (ABO) can cause drug interactions, the effects of ABO on the pharmacokinetics of five cytochrome P450 (CYP) probe drugs were evaluated. Rats were given a single oral dose (2.5 mL/kg BW) of ABO 1 h before administration of a drug cocktail either orally or intravenously, and blood was collected at various time points. A single oral dose of ABO administration did not affect the pharmacokinetics of five probe drugs when given as a drug cocktail intravenously. However, ABO increased plasma theophylline (+28.4%), dextromethorphan (+48.7%), and diltiazem (+46.7%) when co-administered an oral drug cocktail. After 7 days of feeding with an ABO-containing diet, plasma concentrations of theophylline (+45.4%) and chlorzoxazone (+53.6%) were increased after the oral administration of the drug cocktail. The major CYP enzyme activities in the liver and intestinal tract were not affected by ABO treatment. Results from this study indicate that a single oral dose or short-term administration of ABO may increase plasma drug concentrations when ABO is given concomitantly with drugs. ABO is likely to enhance intestinal drug absorption. Therefore, caution is needed to avoid food–drug interactions between ABO and co-administered drugs.

Effects of Ginkgo biloba Extract Ingestion on the Pharmacokinetics of Talinolol in Healthy Chinese Volunteers

2009 ◽  
Vol 43 (5) ◽  
pp. 944-949 ◽  
Author(s):  
Lan Fan ◽  
Gong-You Tao ◽  
Guo Wang ◽  
Yao Chen ◽  
Wei Zhang ◽  
...  
Keyword(s):  
Oral Dose ◽  
Single Oral Dose ◽  
Ginkgo Biloba ◽  
High Performance ◽  
Plasma Concentrations ◽  
Ginkgo Biloba Extract ◽  
Maximum Plasma ◽  
Time Curve ◽  
P Glycoprotein

Background Ginkgo biloba extract (GBE), the best selling herbal medicine in the world, has been reported to inhibit P-glycoprotein in vitro. However, the effects of GBE on P-glycoprotein activity in humans have not been clarified. Objective To investigate the effects of single and repeated GBE ingestion on the oral pharmacokinetics of talinolol, a substrate drug for P-glycoprotein in humans. Methods Ten unrelated healthy male volunteers were selected to participate in a 3-stage sequential study. Plasma concentrations of talinolol from 0 to 24 hours were measured by high-performance liquid chromatography after talinolol 100 mg was administrated alone, with a single oral dose of GBE (120 mg), and after 14 days of repeated GBE ingestion (360 mg/day). Results A single oral dose of GBE did not affect the pharmacokinetics of talinolol. Repeated ingestion of GBE increased the talinolol maximum plasma concentration (Cmax) by 36% (90% CI 10 to 68; p = 0.025), the area under the concentration-time curve (AUC)0-24 by 26% (90% CI 11 to 43; p = 0.008) and AUC0-∞ by 22% (90% CI 8 to 37; p = 0.014), respectively, without significant changes in elimination half-life and the time to Cmax. Conclusions Our results suggest that long-term use of GBE significantly influenced talinolol disposition in humans, likely by affecting the activity of P-glycoprotein and/or other drug transporters.

scholarly journals Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jackelyn Murray ◽  
Robert J. Hogan ◽  
David E. Martin ◽  
Kathy Blahunka ◽  
Fred D. Sancilio ◽  
...  
Keyword(s):  
Oral Dose ◽  
Single Oral Dose ◽  
Virus Replication ◽  
Mammalian Cells ◽  
Clinical Utility ◽  
Plasma Concentrations ◽  
Hamster Model ◽  
Potential Clinical Utility

AbstractEffective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

Sign in / Sign up

Export Citation Format

Share Document